Assistant Professor of Medicine, Johns Hopkins University School of Medicine
Infectious Disease
Dr. Christopher J. Hoffmann, MD
|
|
Give Review
Christopher Hoffmann is an expert in the field of Infectious Disease. He attended Oregon Health & Science University School of Medicine. Christopher Hoffmann has written publications. He has 38 publications published with PubMed. The lastest publication is: 'CD4 count based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.'
Publications
- CD4 count based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
- Pooling sputum from multiple individuals for Xpert(®) MTB/RIF testing: a strategy for screening high-risk populations.
- Rationale and Evidence for Human Immunodeficiency Virus Treatment as Prevention at the Individual and Population Levels.
- Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
- Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
- CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.
- Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.
- Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa.
- Mortality associated with delays between clinic entry and ART initiation in resource-limited-settings: results of a transition-state model.
- Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa.
- Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa.
- Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
- Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
- Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America.
- Changing predictors of mortality over time from cART start: implications for care.
- Epidemiology of Tuberculosis and HIV: Recent Advances in Understanding and Responses.
- Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.
- Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.
- Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.
- Initial regimens for the treatment-naive patient: current understanding and practice.
- Thyroid function abnormalities in HIV-infected patients.
- Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.
- The next battleground for patient safety: influenza immunization of healthcare workers.
- Neurocysticercosis in Oregon, 1995-2000.
- Four Models of HIV Counseling and Testing: Utilization and Test Results in South Africa.
- Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa.
- Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.
- High Prevalence of Pulmonary Tuberculosis but Low Sensitivity of Symptom Screening among HIV-Infected Pregnant Women in South Africa.
- Psychological distress among recent Russian immigrants in the United States.
- Psychometric properties of a Russian version of the SF-12 Health Survey in a refugee population.
- Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.
- Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
- Hepatitis B and long-term HIV outcomes in coinfected HAART recipients.
- HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.
- Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
- Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.
- A novel HIV treatment model using private practitioners in South Africa.
Schools
Oregon Health Sciences University
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Johns Hopkins University -
Oregon Health & Science University School of Medicine
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1649316373 | |
| NPPES Provider LastName | HOFFMANN | |
| NPPES Provider FirstName | CHRISTOPHER | |
| NPPES Provider ZIPCode | 212052100 | |
| NPPES Provider State | MD | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 67.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1649316373 |
| Last Name Of The Provider | HOFFMANN |
| First Name Of The Provider | CHRISTOPHER |
| View All |
Similar Doctors
|
|
Dr. Melissa L. Fox, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel E. Gallant, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paul G. Auwaerter, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. John Aucott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie B. Trivedi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel N. Blankson, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|